<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04988191</url>
  </required_header>
  <id_info>
    <org_study_id>JS001-ISS-115</org_study_id>
    <nct_id>NCT04988191</nct_id>
  </id_info>
  <brief_title>Toripalimab Plus Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Advanced MSI-H or dMMR Colorectal Cancer</brief_title>
  <official_title>The Efficacy and Safety of Toripalimab Combined With Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Patients With Advanced MSI-H or dMMR Colorectal Cancer: an Open-label, Multicenter, Single-arm, Phase Ib/II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a trial investigating the efficacy and safety of Toripalimab combined with&#xD;
      bevacizumab and chemotherapy as neoadjuvant therapy in patients with advanced microsatellite&#xD;
      instability-high (MSI-H) or DNA mismatch repair-deficient (dMMR) colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 24, 2020</start_date>
  <completion_date type="Anticipated">December 24, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 24, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete response rate based on blinded, independent, central review</measure>
    <time_frame>10 weeks</time_frame>
    <description>Percentage of patients who achieve pathological complete response (pCR) based on blinded, independent, central review (BICR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>R0 recession rate</measure>
    <time_frame>10 weeks</time_frame>
    <description>Percentage of patients who achieve R0 recession.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to surgery</measure>
    <time_frame>10 weeks</time_frame>
    <description>Measure of time from study treatment to surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological complete response rate assessed by local investigator</measure>
    <time_frame>10 weeks</time_frame>
    <description>Percentage of patients who achieve pathological complete response (pCR) based on assessment of local investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological complete response rate based on blinded, independent, central review (BICR) and the assessment of local investigator</measure>
    <time_frame>10 weeks</time_frame>
    <description>Percentage of patients who achieve pathological complete response (pCR) based on both blinded, independent, central review (BICR) and assessment of local investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor regression grade (TRG)</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Percentage of patients who achieve partial response (PR) or complete response (CR) based on Response Evaluation Criteria In Solid Tumors (RECIST).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event free survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Measure of time from study treatment to disease progression or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Measure of time from the date of surgery to disease relapse or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One-year or two-year disease-free survival rate</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Percentage of patients who achieve disease-free survival lasting for more than one and two years respectively from the date of surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One-year or two-year overall survival rate</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Percentage of patients who achieve survival for more than one and two years respectively from date of first dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of life quality</measure>
    <time_frame>Until 30 days after the last treatment</time_frame>
    <description>Accessment of life quality based on EORTC QLQ-C30 and EORTC QLQ-CR29 scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Related Adverse Events</measure>
    <time_frame>Until 30 days after the last treatment</time_frame>
    <description>Number of adverse events.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Colorectal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Toripalimab combined with bevacizumab and chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toripalimab</intervention_name>
    <description>Neoadjuvant therapy: Toripalimab is given by intravenous infusion at 3mg/kg d1 every 2 weeks for 3 cycles.&#xD;
Adjuvant therapy: Toripalimab is given by intravenous infusion at a dose of 240mg every 3 weeks for up to 9 cycles.</description>
    <arm_group_label>Toripalimab combined with bevacizumab and chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Neoadjuvant therapy: Bevacizumab is given by intravenous infusion at 5mg/kg d1 every 2 weeks for 3 cycles.</description>
    <arm_group_label>Toripalimab combined with bevacizumab and chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Neoadjuvant therapy: Irinotecan is given by intravenous infusion at 180mg/m2 d1 every 2 weeks for 2 cycles.</description>
    <arm_group_label>Toripalimab combined with bevacizumab and chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed colorectal adenocarcinoma meeting any of the following&#xD;
             criterion: a) T3-4 resectable rectal cancer; b) T1-2 rectal cancer located within 12&#xD;
             cm from the anal verge and refusing direct surgery or radiation therapy; c) T4a-b&#xD;
             resectable colon cancer.&#xD;
&#xD;
          2. Microsatellite instability-high (MSI-H) or DNA mismatch repair-deficient (dMMR).&#xD;
&#xD;
          3. Measurable disease according to the Response Evaluation Criteria In Solid Tumors&#xD;
             (RECIST) 1.1 criteria and haven't received any local treatment.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) 0-1.&#xD;
&#xD;
          5. Fully aware of this study and having signed informed consent.&#xD;
&#xD;
          6. Age 18 to 75 years old without gender limitation.&#xD;
&#xD;
          7. Good compliance.&#xD;
&#xD;
          8. Absolute neutrophil count ≥1500/mm3, platelet ≥100,000/mm3, Hb ≥10g/dl, serum&#xD;
             creatinine ≤1.5 times ULN, creatinine clearance rate ≥50mL/min, ALT and AST ≤2.5 times&#xD;
             ULN, INR or aPTT ≤1.5 times ULN (INR ≤2 times ULN and aPTT in normal range for&#xD;
             patients who are on prophylactic anticoagulant therapy within 14 days before study&#xD;
             treatment), total bilirubin level ≤2 times ULN (within 7 days before study treatment).&#xD;
&#xD;
          9. Women of childbearing age should confirm that serum pregnancy test is negative and&#xD;
             agree to use effective contraceptive methods during study treatment and the following&#xD;
             60 days.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previously received anti-PD1 or anti-PDL1 or anti-PDL2 or anti-CTLA4.&#xD;
&#xD;
          2. Uncontrolled active bleeding from the primary tumor or intestinal obstruction.&#xD;
&#xD;
          3. Contraindications of bevacizumab or irinotecan.&#xD;
&#xD;
          4. Hypersensitivity to other monoclonal antibodies.&#xD;
&#xD;
          5. Any active, known or suspected autoimmune disease.&#xD;
&#xD;
          6. Uncontrolled pleural effusion, pericardial effusion, or ascites to a moderate or&#xD;
             greater extent.&#xD;
&#xD;
          7. History of one of the following dieases: idiopathic pulmonary fibrosis, organized&#xD;
             pneumonia (eg. bronchiolitis obliterans), drug-induced pneumonia, idiopathic pneumonia&#xD;
             and interstitial pneumonia, or evidence of active pneumonia through enhanced chest CT&#xD;
             screening.&#xD;
&#xD;
          8. Major surgery within 4 weeks before enrollment and haven't fully recovered from the&#xD;
             previous surgery.&#xD;
&#xD;
          9. Active bleeding or abnormal coagulation (aPTT &gt;43s or INR &gt;1.5 times ULN), or having a&#xD;
             tendency to bleed or receiving thrombolytic or anticoagulant therapy.&#xD;
&#xD;
         10. Previously received allogeneic stem cell or parenchymal organ transplantation.&#xD;
&#xD;
         11. Any significant clinical or laboratory abnormality that the investigator considers to&#xD;
             influence the safety assessment, eg. uncontrolled active infection, uncontrolled&#xD;
             diabetes, hypertension that cannot be reduced to normal range with monotherapy, grade&#xD;
             II or above peripheral neuropathy, congestive heart failure, heart disease (class II&#xD;
             or higher) as defined by the New York College of Cardiology, myocardial infarction&#xD;
             within 3 months prior to enrollment, unstable arrhythmias, unstable angina pectinis,&#xD;
             chronic kidney disease, abnormal thyroid function and previous or co-existing&#xD;
             malignancies.&#xD;
&#xD;
         12. History of uncorrected serum electrolyte disturbances such as potassium, calcium and&#xD;
             magnesium.&#xD;
&#xD;
         13. HIV infection.&#xD;
&#xD;
         14. Active hepatitis B or hepatitis C.&#xD;
&#xD;
         15. Pregnancy or lactation period, or unwilling to use contraception during the trial.&#xD;
&#xD;
         16. With other malignancy within 5 year, except cervical carcinoma in situ, basal or&#xD;
             squamous skin cancer, local prostatic carcinoma and ductal carcinoma in situ.&#xD;
&#xD;
         17. Use corticosteroids (dose of prednisone or similar drugs&gt; 10mg/day) or other&#xD;
             immunosuppressive agents within 14 days before enrollment.&#xD;
&#xD;
         18. Patients with active tuberculosis (TB) who are receiving anti-TB treatment or have&#xD;
             received anti-TB treatment within 1 year.&#xD;
&#xD;
         19. Active infection, or treatment with oral or intravenous antibiotics within the first 2&#xD;
             weeks prior to neoadjuvant therapy, except prophylactic administration.&#xD;
&#xD;
         20. Anti-infective vaccine (eg. influenza vaccine, varicella vaccine, etc.) injection&#xD;
             within 4 weeks before neoadjuvant therapy.&#xD;
&#xD;
         21. Previous participation in other clinical trials within 4 weeks before neoadjuvant&#xD;
             therapy.&#xD;
&#xD;
         22. Any other disease, metabolic disorder, abnormal physical examination or abnormal&#xD;
             laboratory results that may contrainn the use of trial drug, or affect the reliability&#xD;
             of study results, or lead to high risk of treatment complications, or affect patient&#xD;
             compliance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Shen, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Cancer Hospital &amp; Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lin Shen, Professor</last_name>
    <phone>86-10-88196561</phone>
    <email>linshenpku@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jian Li, Professor</last_name>
    <phone>86-10-88196561</phone>
    <email>oncogene@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University Cancer Hospital and Institute</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Shen, Professor</last_name>
      <phone>86-10-88196561</phone>
      <email>Linshenpku@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Jian Li, Professor</last_name>
      <phone>86-10-88196561</phone>
      <email>oncogene@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Lin Shen, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 31, 2021</study_first_submitted>
  <study_first_submitted_qc>July 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2021</study_first_posted>
  <last_update_submitted>July 31, 2021</last_update_submitted>
  <last_update_submitted_qc>July 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Shen Lin</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

